Drug
Tanimilast clinical trials
Also written CHF6001.
- studies test it
- 15
- open now
- 0
- in phase 3
- 2
- first study started
- 2012
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
15 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2014 | 1 |
| 2016 | 3 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 6
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tanimilast is read from its arms, and is right about nine times in ten.
Testing it · 15
- A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)TerminatedPhase 3Chiesi Farmaceutici S.p.A.NCT04636814Written as CHF6001 1600µg
- Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance TherapyTerminatedPhase 2Chiesi Farmaceutici S.p.A.NCT06029595Written as Experimental: CHF6001 3200 μg
- A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)TerminatedPhase 3Chiesi Farmaceutici S.p.A.NCT04636801Written as Experimental: CHF6001 1600µg
- A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001CompletedPhase 2Chiesi Farmaceutici S.p.A.NCT06900816Written as CHF 6001
- Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) StudyCompletedPhase 1Chiesi Farmaceutici S.p.A.NCT06892756Written as CHF6001 dry powder inhaler (DPI)
- Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy VolunteersCompletedPhase 1Chiesi Farmaceutici S.p.A.NCT06395610Written as CHF6001 DPI
- Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control SubjectsCompletedPhase 1Chiesi Farmaceutici S.p.A.NCT05373953Written as CHF6001
- Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy SubjectsCompletedPhase 1Chiesi Farmaceutici S.p.A.NCT04756960Written as CHF6001
- Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)CompletedPhase 1Chiesi Farmaceutici S.p.A.NCT04739774Written as CHF6001 DPI
- Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPDCompletedPhase 2Chiesi Farmaceutici S.p.A.NCT03004417Written as CHF 6001 Dose1
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001CompletedPhase 1Chiesi Farmaceutici S.p.A.NCT02386761Written as Single Ascending Dose (SAD)
- A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPDCompletedPhase 2Chiesi Farmaceutici S.p.A.NCT02986321Written as CHF6001
- A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in AsthmaticsCompletedPhase 2Chiesi Farmaceutici S.p.A.NCT01689571Written as CHF6001
- Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD PatientsCompletedPhase 2Chiesi Farmaceutici S.p.A.NCT01730404Written as CHF6001 DPI
- Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001CompletedPhase 1Chiesi Farmaceutici S.p.A.NCT03004495Written as CHF5259 and CHF6001